Update to contractual arrangements between 澳门在线赌城娱乐, Swedish Orphan Biovitrum AB and Sanofi

2023年4月11日07:00英国夏令时
 

澳门在线赌城娱乐, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the 发展 and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of relevant parties.  

根据最新安排, Sobi has entered into a direct relationship with Sanofi, replacing the previous participation 协议 with 澳门在线赌城娱乐 entered into in 2018年11月. 根据之前的协议, from the day of the transaction with Sobi, 澳门在线赌城娱乐 had to provision the risk adjusted value of the discounted cash flow of future payments to be made to Sobi as a liability. As a result of this simplification 协议, Sanofi will pay royalties to Sobi as US nirsevimab sales arise, and the liability related to future obligations is eliminated. 澳门在线赌城娱乐将录得0美元的收益.7 billion, to be recognised in Core Other operating income in 2023. This does not impact 澳门在线赌城娱乐’s financial guidance for 2023.

笔记

关于nirsevimab
Nirsevimab is a single dose long-acting antibody, developed and commercialised in partnership by 澳门在线赌城娱乐 and Sanofi using 澳门在线赌城娱乐’s YTE technology. It is designed to protect infants entering or during their first respiratory syncytial virus (RSV) season and for children up to 24 months of age who r教育津贴in vulnerable to severe RSV disease through their second RSV season. Nirsevimab has been developed to offer newborns and infants direct RSV protection via an antibody to help prevent lower respiratory tract disease (LRTD) caused by RSV. Monoclonal antibodies do not require the activation of the immune system to help offer timely, rapid and direct protection against disease.¹

2022年11月， Beyfortus was approved by the 欧洲委员会 and by the UK 药物 and 保健产品监管机构 (MHRA).^2-3

赛诺菲安万特联盟
In March 2017, 澳门在线赌城娱乐 and Sanofi announced an 协议 开发和商业化nirsevimab. 根据协议条款, 澳门在线赌城娱乐 leads 发展 and manufacturing activities, and Sanofi leads commercialisation activities and records revenue. 根据全球协议的条款, 赛诺菲支付了1.2亿欧元的预付款, has paid a 发展 milestone of €30m and will pay further milestones subject to achievement of certain 发展 and sales-related milestones. The two companies share costs and profits. Revenue from the 协议 is reported as Alliance Revenue and Collaboration Revenue in the Company’s financial statements.

艺人事务
In 2018年11月, 澳门在线赌城娱乐 announced that it had agreed to sell the US commercial rights for Synagis (palivizumab), and the right to participate in the US profits or losses for nirsevimab, 致Sobi(2018年公告).

Today’s announcement is made pursuant to LR10.4.2 R in respect of the 2018年11月 announcement. 除了本公告中规定的, t在这里 has been no significant change affecting any matter contained in the 2018 announcement and no other significant new matter has arisen which would have been required to be mentioned in the 2018 announcement if it had arisen at the time of the preparation of the 2018 announcement.

澳门在线赌城娱乐
澳门在线赌城娱乐 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, 发展, and commercialisation of prescription medicines in 肿瘤学, 罕见疾病, 和澳门第一赌城在线娱乐, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com 并在推特上关注公司 @澳门在线赌城娱乐.

联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.

参考文献。

艾德里安·坎普
公司秘书
澳门在线赌城娱乐